# State Impulsivity and Substance Use: A Systematic Review and Meta-Analysis Protocol | PLOS One > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/state-impulsivity-substance-use-review-protocol/ > **Published:** 2026-04-07T19:03:03-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:28:04-04:00 > **Clinical Summary:** Explore the state impulsivity substance use relationship in this systematic review protocol to inform therapeutic targeting and risk stratification. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic AddictionMental HealthRisk AssessmentBehavioral Health[Clinical Research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) Why This Matters Impulsivity represents a core clinical dimension underlying substance use disorders, influencing both initiation and maintenance of problematic use patterns. Systematic understanding of this relationship informs therapeutic targeting and risk stratification in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) practices. Clinical Summary This protocol outlines a planned systematic review and meta-analysis examining the relationship between state impulsivity and substance use behaviors. State impulsivity refers to momentary, situational variations in impulse control, distinct from trait impulsivity which represents stable personality characteristics. The review aims to quantify associations between acute impulsive states and substance use outcomes across different populations and substances. Current evidence suggests state impulsivity may be more modifiable than trait measures, potentially offering therapeutic intervention points. Dr. Caplan’s Take “We need better tools to identify when patients are most vulnerable to problematic use patterns. If state impulsivity proves predictive and modifiable, it could reshape how we time interventions and monitor treatment response.” Clinical Perspective 🧠 Clinicians should consider assessing situational factors that heighten impulsivity during patient encounters, particularly stress, sleep deprivation, and emotional dysregulation. This research direction may eventually inform real-time intervention strategies and help patients recognize their own vulnerability windows for substance use escalation. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20State%20impulsivity%20and%20substance%20use%3A%20A%20systematic%20review%20and%20meta-analysis%20proto...%20%40drcaplan&url=https%3A//journals.plos.org/plosone/article%3Fid%3D10.1371/journal.pone.0346779)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//journals.plos.org/plosone/article%3Fid%3D10.1371/journal.pone.0346779)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20State%20impulsivity%20and%20substance%20use%3A%20A%20systematic%20review%20and%20meta-analysis%20proto...%20--%20via%20%40drcaplan.bsky.social%20https%3A//journals.plos.org/plosone/article%3Fid%3D10.1371/journal.pone.0346779)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0346779](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0346779) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating of this cannabis research?](#What_is_the_clinical_relevance_rating_of_this_cannabis_research) - [What medical areas does this cannabis research cover?](#What_medical_areas_does_this_cannabis_research_cover) - [Why is this cannabis news considered clinically significant?](#Why_is_this_cannabis_news_considered_clinically_significant) - [How does this research relate to addiction treatment?](#How_does_this_research_relate_to_addiction_treatment) - [What should clinicians know about the mental health aspects of this research?](#What_should_clinicians_know_about_the_mental_health_aspects_of_this_research) - [Related](#Related) ## FAQ #### What is the clinical relevance rating of this cannabis research? This research has been assigned a CED Clinical Relevance rating of #70, indicating “Notable Clinical Interest.” This classification suggests emerging findings or policy developments that are worth monitoring closely by healthcare professionals. #### What medical areas does this cannabis research cover? The research focuses on several key areas including addiction, mental health, risk assessment, and behavioral health. These interconnected fields highlight the comprehensive nature of cannabis-related medical considerations. #### Why is this cannabis news considered clinically significant? The research represents emerging findings that warrant close monitoring by clinicians. The “Notable Clinical Interest” designation indicates potential implications for [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) and treatment decisions. #### How does this research relate to addiction treatment? The study’s focus on addiction suggests it may provide insights into [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) patterns, dependency risks, or treatment approaches. This information could be valuable for healthcare providers managing patients with substance use concerns. #### What should clinicians know about the mental health aspects of this research? The mental health component indicates the research addresses psychological effects or therapeutic applications of cannabis. Clinicians should monitor these findings for potential impacts on psychiatric treatment protocols and patient safety considerations. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Genetic nurture in intergenerational transmission of substance use | Nature Communications](https://cedclinic.com/genetic-nurture-substance-use-intergenerational-risk/) Explore how genetic and environmental factors contribute to substance use across generations, complementing insights on impulsivity and substance use. [Read More](https://cedclinic.com/genetic-nurture-substance-use-intergenerational-risk/) [Dr. Dan Brennan: Adolescent Cannabis Use and Rising Risk of Mental Health Disorders](https://cedclinic.com/adolescent-cannabis-use-mental-health-risk/) Understand [adolescent cannabis use](https://cedclinic.com/adolescent-cannabis-use-and-anxiety-research/) and its mental health risks, providing context for impulsivity-related substance use research. [Learn More](https://cedclinic.com/adolescent-cannabis-use-mental-health-risk/) [High-Potency Cannabis Linked to Dramatically Higher Risk of Psychotic Episodes](https://cedclinic.com/high-potency-thc-cannabis-risk-psychotic-episodes/) Review findings on cannabis potency and psychosis risk, relevant to behavioral health and impulsivity in substance use. [Explore Study](https://cedclinic.com/high-potency-thc-cannabis-risk-psychotic-episodes/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).